Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years old and ≤75 years old, regardless of gender;~* patients weighing ≥ 40 kg;~* Patients diagnosed with PAH in Group 1 of the WHO Updated Clinical Classification of Pulmonary Hypertension (WHO functional class II or III);~* 6 min walk test (6MWT), walking distance ≥ 50 m;~* Right heart catheterization performed within 6 months prior to screening and meeting the following hemodynamic criteria:~  1. mean pulmonary artery pressure ≥ 25 mm Hg；~ 2. Pulmonary vascular resistance ≥ 240 dyn·s·cm-5;~ 3. Pulmonary artery wedge pressure or left ventricular end-diastolic pressure ≤ 15 mmHg;~* Subject receiving calcium channel blocker (CCB) drugs, only those whose doses have been stabilized for more than 4 weeks at the time of screening are allowed to be included in the study;~* Pulmonary function testing performed within 6 months prior to screening and meeting the following criteria：~  1. Total lung capacity ≥ 60% of normal predicted value;~ 2. Forced expiratory volume in one second (FEV1) ≥ 55% of normal expected value;~* Female subjects of childbearing potential must have a negative pregnancy test at the Screening Visit and Day 0;~* Females subjects of childbearing potential must use a medically acceptable method of contraception (eg, hormone therapy, IUD, barrier methods such as condoms or cervical caps) during the study;~* Sign written informed consent~Exclusion Criteria:~* Patients diagnosed with WHO updated PH clinical classification of group 2, 3, 4, 5;~* Endothelin receptor antagonist therapy (eg, bosentan) has been discontinued prior to enrollment due to safety or tolerability concerns (non-drug-induced liver function abnormalities);~* Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \> 2 times ULN;~* Serum bilirubin level \> 1.5 times ULN;~* severe hepatic insufficiency (Child-Pugh class C);~* severe renal insufficiency (creatinine clearance \<30 mL/min);~* Hemoglobin concentration \< 10 g/dL or hematocrit \< 30%;~* Contraindications to treatment identified by laboratory tests, physical examination, medical history, or other investigations~* severe hypotension (diastolic \< 50 mm Hg or systolic \< 90 mm Hg);~* Clinically significant aortic or mitral valve disease, pericardial constriction, restrictive or congestive cardiomyopathy, fatal arrhythmias, LV ejection fraction \< 45%, LV outflow tract obstruction, symptomatic coronary heart disease, spontaneously low blood pressure;~* A history of malignancy within 5 years prior to enrollment, except for basal cell carcinoma of the skin and carcinoma in situ of the cervix;~* Subject taking endothelin receptor antagonists such as ambrisentan, bosentan and macitentan within 4 weeks prior to enrollment;~* pregnant and lactating women;~* Subject deemed unsuitable for participation in this study by other investigators

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ambrisentan (Type: EXPERIMENTAL): Open Label

Based on this trial design, predict the completion outcome and termination type (if applicable).